Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CELIXIR10
- Development stage
- Phase 3
- Lead developer
- BOL Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CELIXIR10** is a BOL Pharma cannabinoid-based medicated-drop product formulated with approximately 5% delta-9-tetrahydrocannabinol and 10% cannabidiol. It is part of BOL Pharma's standardized cannabis-extract and purified-cannabinoid drop portfolio, intended for medical use including cancer pain and chemotherapy-induced nausea and vomiting. The product's therapeutic activity is attributable to combined cannabinoid pharmacology, although BOL Pharma does not specify a product-level molecular mechanism for CELIXIR10. ([bolpharma.com](https://www.bolpharma.com/medicated-drops/))
- Brand names
- CELIXIR10CELIXIR-10CELIXIR 10
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHPPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on CELIXIR10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CELIXIR10.